A diagnostic model incorporating p50 sensory gating and neuropsychological tests for schizophrenia.

Department of Psychiatry, Cathay General Hospital, Taipei, Taiwan
PLoS ONE (Impact Factor: 3.53). 02/2013; 8(2):e57197. DOI: 10.1371/journal.pone.0057197
Source: PubMed

ABSTRACT Endophenotypes in schizophrenia research is a contemporary approach to studying this heterogeneous mental illness, and several candidate neurophysiological markers (e.g. P50 sensory gating) and neuropsychological tests (e.g. Continuous Performance Test (CPT) and Wisconsin Card Sorting Test (WCST)) have been proposed. However, the clinical utility of a single marker appears to be limited. In the present study, we aimed to construct a diagnostic model incorporating P50 sensory gating with other neuropsychological tests in order to improve the clinical utility.
We recruited clinically stable outpatients meeting DSM-IV criteria of schizophrenia and age- and gender-matched healthy controls. Participants underwent P50 sensory gating experimental sessions and batteries of neuropsychological tests, including CPT, WCST and Wechsler Adult Intelligence Scale Third Edition (WAIS-III).
A total of 106 schizophrenia patients and 74 healthy controls were enrolled. Compared with healthy controls, the patient group had significantly a larger S2 amplitude, and thus poorer P50 gating ratio (gating ratio = S2/S1). In addition, schizophrenia patients had a poorer performance on neuropsychological tests. We then developed a diagnostic model by using multivariable logistic regression analysis to differentiate patients from healthy controls. The final model included the following covariates: abnormal P50 gating (defined as P50 gating ratio >0.4), three subscales derived from the WAIS-III (Arithmetic, Block Design, and Performance IQ), sensitivity index from CPT and smoking status. This model had an adequate accuracy (concordant percentage = 90.4%; -statistic = 0.904; Hosmer-Lemeshow Goodness-of-Fit Test, = 0.64>0.05).
To the best of our knowledge, this is the largest study to date using P50 sensory gating in subjects of Chinese ethnicity and the first to use P50 sensory gating along with other neuropsychological tests to develop a diagnostic model for schizophrenia. Further research to validate the predictive accuracy of this model by applying it on other samples is warranted.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Once adequate reliability has been achieved, however, it is important to document internal consistency and external validity. This chapter has summarized some of our work with the former topic. It suggests that the SANS has high internal consistency, while the SAPS is somewhat less internally consistent. What are the clinical and research implications of these results concerning internal consistency? On a superficial and statistical level, these results might be considered to suggest that the SAPS is less valid than the SANS, and perhaps that therefore it is not useful. On the other hand, it might be argued that it is not necessary to measure all the items on the SANS, since they are highly intercorrelated with one another and any one might 'stand in place' for the others. While in a sense statistically correct, these conclusions are probably misleading in both clinical and research settings. The SANS and SAPS were designed primarily as descriptive instruments that are useful for encoding symptoms commonly observed in psychiatric patients. Essentially, these results document clinical common sense. Patients with one negative symptom tend to have several others, while patients with one positive symptom do not necessarily have others. In other words, affective flattening seems to be related to alogia and avolition, but delusions and hallucinations do not necessarily occur together. In a comprehensive description of an individual patient, it is important to document all the types of symptoms that are present. This is particularly crucial in pharmacologic studies, where one may wish to document that some symptoms or groups of symptoms are more responsive to treatment than are other symptoms. For example, although anhedonia and alogia are statistically correlated with one another in a population of schizophrenics, in an individual patient anhedonia might be more responsive to treatment with a specific medication than is alogia. In spite of the high intercorrelations, it remains important in clinical settings to evaluate all relevant symptoms. The results of the factor analyses in this second study do not suggest as clean and strong a separation between positive and negative symptoms as was indicated in our original study. Factor analysis is notoriously sample-dependent, but there is no reason to suspect that the sample in the second study was different in any way from that of the first. Both involved consecutive admissions of DSM-III schizophrenics to the Iowa Psychiatric Hospital. The individuals doing the clinical evaluation did change, however.(ABSTRACT TRUNCATED AT 400 WORDS)
    Modern problems of pharmacopsychiatry 02/1990; 24:73-88.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Continuous Performance Test (CPT) has been modified to be used widely as a potential vulnerability marker of schizophrenia. In genetic analyses of schizophrenia, well-established norms for the CPT are essential in choosing a suitable threshold of CPT for classifying subjects as affected or unaffected. In this study, we investigated the performance of 115 adolescents and 345 adults, randomly sampled from a community, on two sessions of the CPT 1-9 (undegraded and 25% degraded). The results showed that an older age was associated with a decreasing hit rate and sensitivity (d'), while a higher level of education was associated with an increasing hit rate and d' for both sessions of the CPT. Men had higher hit rates and d' than women for the degraded CPT. A practice effect during the second session of the CPT was noted among 20 to 33 percent of the subjects. Poorer CPT performance was associated with schizotypy measured by the Perceptual Aberration Scale and the Schizotypal Personality Questionnaire. Thus, in assessing CPT performance among schizophrenia patients or high-risk populations, we must compare their results to age-, education-, and sex-corresponding norms. The data presented in this report will be valuable in this regard.
    Schizophrenia Bulletin 01/1998; 24(1):163-74. · 8.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Because many schizophrenic patients are heavy smokers, it has been suggested that nicotine normalizes some neuronal deficit involved in their illness. Schizophrenic subjects have various difficulties with maintenance of attention and selective processing of sensory information. One defect in sensory gating in schizophrenia has been characterized by recording auditory evoked potentials. Most normal subjects have a decrease in the evoked response to the second of two closely paired stimuli, whereas most schizophrenic subjects do not. The aim of this study was to determine whether smoking normalizes this deficit in auditory sensory gating in schizophrenia. Changes in auditory sensory gating in response to smoking cigarettes were studied in 10 smokers without psychiatric illness and 10 schizophrenic smokers. Both groups were asked to abstain from smoking from 11:00 p.m. until 8:00 a.m. the next morning, when their auditory evoked responses to pairs of clicks were recorded. The ability to gate sensory information is reflected in a decrease in the P50 wave amplitude in response to the second of the two stimuli. After baseline recordings, the subjects smoked as much as they wished, and then two postsmoking recordings were performed. The schizophrenic patients had a marked but brief improvement in P50 auditory gating immediately after smoking, whereas P50 gating for the normal smokers was slightly impaired. This study suggests that cigarette smoking can transiently normalize the impairment of auditory sensory gating in schizophrenic patients.
    American Journal of Psychiatry 01/1994; 150(12):1856-61. · 13.56 Impact Factor

Full-text (2 Sources)

Available from
May 28, 2014

Jia-Chi Shan